Overview of Influenza and Pneumococcal Vaccines by Brooks, Krista
Southwestern Oklahoma State University
SWOSU Digital Commons
Faculty Articles & Research Pharmacy Practice
10-24-2015
Overview of Influenza and Pneumococcal Vaccines
Krista Brooks
Southwestern Oklahoma State University, krista.brooks@swosu.edu
Follow this and additional works at: https://dc.swosu.edu/cop_pp_articles
This Article is brought to you for free and open access by the Pharmacy Practice at SWOSU Digital Commons. It has been accepted for inclusion in
Faculty Articles & Research by an authorized administrator of SWOSU Digital Commons. An ADA compliant document is available upon request. For
more information, please contact phillip.fitzsimmons@swosu.edu.
Recommended Citation
Brooks, Krista, "Overview of Influenza and Pneumococcal Vaccines" (2015). Faculty Articles & Research. 12.
https://dc.swosu.edu/cop_pp_articles/12
Influenza D isease and 
Influenza Vaccines
Krista Brooks, Pharm.D.
Immunization Training Seminar 
Rural Health Network SWOSU College of Pharmacy 
October 24, 2015
Objectives
1. Describe the influenza d isease, including the 
causative agent
2. Identify those  for whom influenza immunization 
is recommended
3. Describe the characteristics of the vaccines  
used to prevent influenza (schedule, 
contraindications, and/or adverse reactions
4. Locate resources relevant to current 
immunization practice
5. Obtain, a s s e s s  and apply patient information to 
determine the need for immunization
Influenza Epidemiology
• Reservoir Human, animals (type A
only)
• Transmission Respiratory
Probably airborne
• Temporal pattern Peak December -  March
in temperate climate 
May occur earlier or later
• Communicability 1 day before to 5 days
after onset (adults)
Influenza Activity in the US 
2012-2013 Season
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6223a5.htm?s_cid=mm6223a5_e#fig2
Influenza Transm ission
• Respiratory 
transm ission of virus
• Person to person  
transm ission  
—Sneezing  
—Coughing
• Viral shedding in 
respiratory secretions 
for 5 -  10 days
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Influenza Clinical Features
• Incubation period 2 days 
(range 1-4 days)
• Abrupt on set of fever, myalgia, sore  
throat, nonproductive cough, 
headache, malaise, rhinitis
• Severity of illness depends on prior 
experience with related variants
Complications of Influenza
• Complications: pneumonia - most 
common; Reye syndrom e (children); 
myocarditis
• Groups m ost at risk for flu: elderly, 
pediatrics, and those with chronic illness
• 20 - 60% of high-risk groups vaccinated; 
10,000 - 40,000 deaths/year
Impact of Influenza- United States 
1976 - 2007
• T h e  n u m b e r  o f  i n f lu e n z a - a s s o c ia t e d  d e a t h s  
v a r ie s  s u b s t a n t ia l l y  b y  y e a r , in f lu e n z a  v ir u s  
t y p e  a n d  s u b t y p e ,  a n d  a g e  g r o u p
• A n n u a l i n f lu e n z a - a s s o c ia t e d  d e a t h s  r a n g e d  
fr o m  3 ,3 4 9  ( 1 9 8 5 -8 6  s e a s o n )  t o  4 8 ,6 1 4  
( 2 0 0 3 -0 4  s e a s o n ) ,  w ith  a n  a v e r a g e  o f  2 3 ,6 0 7  
a n n u a l  d e a t h s
• P e r s o n s  6 5  y e a r s  o f  a g e  a n d  o ld e r  a c c o u n t  fo r  
a p p r o x im a t e ly  9 0 %  o f  d e a t h s
• 2 .7  t im e s  m o r e  d e a t h s  o c c u r r e d  d u r in g  
s e a s o n s  w h e n  A (H 3 N 2 ) v i r u s e s  w e r e  
p r o m in e n t
Impact of Influenza
• Rates of hospitalization among 
children 2 years and younger are 
similar to th ose  of persons 65 and 
older with high-risk medical 
conditions
• Children 24 through 59 months of age  
are at increased risk for influenza- 
related clinic and em ergency  
department visits
Groups at Increase Risk of 
Complications of Influenza
• All children 6 months through 4 years of 
age
• All persons 50 years of age or older
• Persons 6 m onths of age and older with 
underlying medical conditions, particularly 
cardiovascular, pulmonary and metabolic 
conditions
• Im m unosuppression
• R esidents of long-term care facilities
• Pregnant women
Groups at Increase Risk of 
Complications of Influenza, 
continued
• Children 6 months through 18 years 
and receiving long-term aspirin 
therapy -  increased risk for Reye 
syndrom e
• American Indians/Alaska Natives
• Morbidly o b ese  (BMI > 40)
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US Hospitalization Rates for 
Influenza
October 1, 2012-April 30, 2013
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6223a5.htm?s_cid=mm6223a5_e#fig2
Influenza Virus Strains
• T yp e A - moderate to severe illness
- all age groups
- humans and other animals
• T yp e B - milder d isease
- primarily affects children
- humans only
• T yp e C - rarely reported in humans
- no epidem ics
Influenza Virus Influenza Antigenic Changes
• Antigenic Drift
—minor change, sam e subtype  
—caused  by point mutations in gene  
—may result in epidem ic
• Example of antigenic drift
- in  2002-2003, A/Panama/2007/99 
(H3N2) virus w as dominant
-A/Fujian/411/2002 (H3N2) appeared 
in late 2003 and caused  widespread  
illness in 2003-2004
Influenza Antigenic Changes
• Antigenic Shift 
—major change, new subtype
—caused  by exchange of gene  
segm en ts
—may result in pandemic
Influenza Type A Antigenic Shifts
Year Subtype
Severity of 
Pandemic
1889 H3N2 Moderate
1918 H1N1 Severe
1957 H2N2 Severe
1968 H3N2 Moderate
1977 H1N1 Mild
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Influenza Pandem ics
P a n d e m i c D e a t h s  i n  U S
S p a n i s h  flu  (H 1 N 1 ) 1 9 1 8 -1 9 1 9 6 7 5 ,0 0 0
A s ia n  flu  (H 2 N 2 ) 1 9 5 7 -1 9 5 8 7 0 ,0 0 0
H o n g  K o n g  flu  (H 3 N 2 ) 
1 9 6 8 -1 9 6 9
3 4 ,0 0 0
2 0 0 9  H 1N 1 in flu e n z a  
2 0 0 9 -2 0 1 0 *
8 , 8 7 0 -  1 8 ,3 0 0
*Between 43 million - 89 million cases of H1N1
195,000 -  403,000 H1N1 -related hospitalizations
www.flu.gov/general/historicaloverview.html
E stim ated  2009  H1N1 C a s e s ,  
H o sp ita liza tio n s , and D ea th s (April 2009  -  
April 2010 )
Outcome and age group Mid-level Range Estimated Range
I lln e s se s
0-17 years 20,000,000 14 -28 million
18-64 years 35,000,000 25 - 52 million
65 and older 6,000,000 4 - 9  million
Total illnesses 61,000,000 43 - 89 million
Hospitalizations
0-17 years 87,000 62-128  thousand
18-64 years 160,000 114-235 thousand
65 and older 27,000 19 - 40 thousand
Total hospitalizations 270,000 195 - 403 thousand
Deaths
0-17 years 1,280 910 - 1880
18-64 years 9,570 6,800 -  14,040
65 and older 1,620 1,160 - 2,380
Total Heaths 12,470 8,870 -18,300
www.cdc.gov/h1n1flu/estimates2009_h1n1.htm
Prevention of Influenza
• T he m o s t  e f fe c tiv e  s tr a te g y  for  
p reven tin g  in flu en za  and its 
c o m p lic a tio n s  is  ann u al v a cc in a tio n
• All p e r so n s  > 6 m o n th s  w h o  d o  n ot  
h a v e  co n tr a in d ic a tio n s  to  th e  v a c c in e  
sh o u ld  r e c e iv e  th e  in flu en za  
v a cc in a tio n
Timing of Influenza Vaccine Programs
• In fluenza  ac tiv ity  can  o c c u r  a s  early  
a s  O ctob er
• In m ore  than 80%  o f s e a s o n s  s in c e  
1976 , peak  in flu en za  ac tiv ity  h a s  n ot  
o ccu rred  until J an u ary  or later
• In m ore  than 60%  o f s e a s o n s  th e  peak  
w a s  in F ebruary  or later
Timing of Influenza Vaccine Programs
• P rov id ers sh o u ld  b eg in  offering  
v a c c in e  s o o n  after it b e c o m e s  
a v a ila b le , if p o s s ib le  by  O cto b er
• To avoid  m is se d  o p p o r tu n itie s  for  
v a c c in a t io n , p rov id ers sh o u ld  offer  
v a c c in e  during routine h ea lth ca re  
v is its  or during h o sp ita liz a tio n s  
w h e n e v e r  v a c c in e  is  a v a ilab le
Timing of Influenza Vaccine Programs
• P e r s o n s  p la n n in g  o r g a n iz e d  v a c c in a t io n  
c a m p a ig n s  sh o u ld  c o n s id e r  s c h e d u lin g  
t h e s e  e v e n t s  a fter at le a s t  m id -O cto b er
• S c h e d u lin g  c a m p a ig n s  a fter m id -O cto b er  
will m in im ize  th e  n e e d  for c a n c e lla t io n s  
b e c a u s e  v a c c in e  is  u n a v a ila b le
• C o n tin u e  to  o ffer  in flu en za  v a c c in e  in 
D e c e m b e r
• P ro v id e rs sh o u ld  c o n t in u e  to  v a c c in a te  
th r o u g h o u t  in flu en za  s e a s o n
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Composition of the 2015-2016 
Influenza Vaccine
• The 2015-2016 seasonal influenza 
vaccine will include
• Trivalent vaccines
—A/California/7/2009 (H1 N1)-like virus
—A/Switzerland/9715293/2013 (H3N2)-like 
virus
-B/Phuket/3073/2013-like virus
• Quadrivalent vaccines 
—3 listed above and 
-B/Phuket/3073/2013-like virus
Influenza Vaccines
* Inactivated influenza vaccine (IIV)
—intramuscular or intradermal 
—trivalent (IIV3) and quadrivalent (IIV4)
* Live attenuated vaccine (LAIV) 
—intranasal
—quadrivalent (LAIV4)
* Recombinant influenza vaccine (RIV) 
—Intramuscular
—trivalent (RIV3)
IIV LAIV RIV
Type o f vaccine Inactivated Live attenuated Recombinant
Route of 
administration
IM injection and 
intradermal (ID) 
injection
Intranasal spray IM injection
Number o f antigens 3 or 4 4 3
Approved age • Intramuscular For 
persons aged > 6 
months*
• Intradermal for 18 
to 64 years
For persons aged 
2 through 49  
years
For persons aged 
18 years or older
Other Information: • Can be used in 
patients with 
chronic medical 
conditions
• Can be used in 
persons who are 
close contacts with 
immunosuppressed 
patients
Only for healthy, 
non-pregnant 
adults
Does not contain 
any egg protein and 
can be given to age- 
appropriate 
persons with egg 
allergy o f any 
severity
*Pharmacists should verify the approved age indication for each individual vaccine
Inactivated Influenza Vaccine (IIV) 
Recommendations
* Advisory Committee on Immunization 
Practices recommends annual influenza 
vaccination for all persons 6 months of age 
and older
* Protection of persons at higher risk for 
influenza-related complications should 
continue to be a focus of vaccination 
efforts as providers and programs 
transition to routine vaccination of all 
persons aged 6 months and older
Influenza Inactivated (IIV)*
* Intramuscular
—standard-dose IIV* -  persons aged 6 
months or older, including pregnant 
women
—high-dose IIV -  persons who are 
aged 65 years or older
• Intradermal IIV -  persons aged 18 
through 64 years
*Pharmacists should verify the approved age indication for each 
individual vaccine
Fluzone High-Dose IIV
• Contains 4 X amount of influenza 
antigen than regular Fluzone
• Approved only for persons 65 years 
and older
• Produced higher antibody levels; 
slightly higher local reactions
• Studies underway to assess clinical 
effectiveness
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Intramuscular Injection Fluzone Intradermal IIV
• Approved only for 
persons 18 through 
64 years of age
• D ose is 0.1 mL 
administered by a 
specially designed  
microneedle 
injector system  in 
the deltoid
Influenza Inactivated (IIV)*
• Contraindications:
—Severe allergic reaction after previous 
d o se  of any influenza vaccine, or to a 
vaccine com ponent including egg  
protein
• Precautions:
—Moderate or severe acute illness with or 
without fever
—History of Guillain-Barre syndrom e 
within 6 w eeks of previous vaccine
Inactivated Influenza Vaccine 
Adverse Reactions
Local reactions 15%-20%
Fever, malaise not com m on
Allergic reactions rare
Neurological
reactions
very rare
Live attenuated influenza vaccine  
(LAIV)
• Intranasal -  healthy, non-pregnant 
persons age 2 to 49 years without 
high-risk medical conditions
• Active inhalation (i.e. sniffing) is not 
required by the patient during vaccine  
administration
• If a patient sn eezes  or blows their 
n ose  after receiving intranasal LAIV; 
Re-vaccination is not necessary.
FluMist
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LAIV Vaccine Administration
• FluMist -  intranasal administration
—Two sprays in sing le  device  
—Patient’s  head slightly tilted back 
—Remove rubber tip
—Insert nasal apparatus just inside one nostril 
and push just until plunger stop s  
—Remove dose-separating clip and second  
spray should be administered into other nostril 
—Do NOT have patient strongly “sniff” vaccine 
into nasal p assage
—Revaccination is NOT necessary in the event of 
nasal discharge or sneezing
Transm ission of LAIV Virus
• LAIV replicates in the nasopharyngeal 
m ucosa
• Mean shedding of virus 7.6 days -  longer 
in children
• Transmitted virus retained attenuated, 
cold-adapted, tem perature-sensitive 
characteristics
• No transm ission of LAIV reported in the 
U.S.
Sim ultaneous Administration of 
LAIV and Other Vaccines
• Inactivated vaccines can be 
administered either sim ultaneously or 
at any time before or after LAIV
• Other live vaccines can be 
administered on the sam e day a s  LAIV
• Live vaccines not administered on the 
sam e day should be administered at 
least 4 w eeks apart
Live attenuated influenza vaccine  
(LAIV)
• Contraindications:
— Severe allergic reaction to any component of the 
vaccine or to a previous dose of any influenza vaccine
— Should not be used in the following populations (ACIP 
recommendation)
• Children 2 through 17 years of age who are receiving aspirin 
therapy
• Children 2 through 4 years who have asthma or wheezing in 
the past 12 months
• Pregnant
• Immunosuppressed adults or caretakers of 
immunosuppressed adults (avoid for 7 days after receiving)
• Adults with egg allergy (any severity)
• Adults who have taken influenza antiviral medication within 
the previous 48 hours -  avoid use of antiviral drugs for 14 
days after vaccination
Live attenuated influenza vaccine  
(LAIV)
• Precautions:
—Moderate or severe acute illness with or 
without fever.
—History of Guillain-Barre syndrom e 
within 6 w eeks of previous vaccine
—Asthma in persons aged 5 years and 
older
—Other chronic medical conditions (lung 
d isease, cardiovascular d isease, 
diabetes, renal or hepatic d isease, 
hem atologic, neurologic, and metabolic 
disorders
Live Attenuated Influenza Vaccine 
Adverse Reactions
• Children
— no significant increase in URI sym ptom s, fever, 
or other system ic sym ptom s
—significantly increased risk of asthm a or 
reactive airways d isea se  in children 12-59 
m onths o f age
• Adults
—significantly increased rate o f cough, runny 
nose, nasal congestion , sore throat, and chills 
reported among vaccine recipients
— no increase in the occurrence of fever
• No serious adverse reactions identified
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Recombinant influenza vaccine  
(RIV)
• Intramuscular -  persons 18 years or 
older
• Does not contain any egg  protein
• Can be give to age-appropriate 
persons with egg  allergy of any 
severity
Recombinant influenza vaccine  
(RIV)
• Contraindications:
—Severe allergic reaction after 
previous d o se  of RIV or to a vaccine  
com ponent
• Precautions:
—Moderate or severe acute illness 
with or without fever
—History of Guillain-Barre Syndrome 
within 6 w eeks of previous 
vaccination
Influenza Vaccination of Children 
6 Months Through 8 Years Of Age
Has the child received >2 
total doses of trivalent or 
quadrivalent influenza 
vaccine before July 1, 2015*
Yes
1 dose of 2015-16 
influenza vaccine
don't know
2 doses* of 2015-16 
influenza vaccine
•The two doses need not have been received during the same season or 
consecutive seasons.
* Doses should be administered >4 weeks apart.
Advisory C om m ittee on  Im m unization  P ractices, U nited States, 
2015-16 influenza season
Influenza Vaccine 
Storage and Handling
• IIV, LAIV, and RIV must be stored at 
refrigerator temperature (35°-46°F, 
2°-8°C)
• V accines should be frozen; Discard if 
product has been frozen
IIV or LAIV?
1. 47 y/o pharmacist who administers 
influenza vaccine the general public; 
no contraindications
2. 38 yom with diabetes
3. 2 y/o healthy female; no 
contraindications
4. Pregnant patient with no 
contraindications
Test your knowledge
Which of the following patients is not a
candidate for the influenza vaccination?
A. 5-month-old female; no medical 
conditions
B. 10-year-old male; recently diagnosed  
with Type 1 DM
C. 80-year-old fem ale with COPD
D. 25-year-old male; no medical 
conditions
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Selected R esources for Vaccine 
Information
• CDC Vaccine information
—http://www.cdc.gov/vaccines/acip/
index.html
• Pink Book
—http://www.cdc.gov/vaccines/pubs/
pinkbook/index.html
• Immunization Action Coalition 
—http://www.immunize.org/vis/
Pneum ococcal 
D isease and V accines
Krista Brooks, Pharm.D. 
Immunization Training Seminar 
Rural Health Network SWOSU College of 
Pharmacy 
October 24, 2015
Objectives
1. Describe d isea ses  caused  by S tep to co ccu s  
pneum oniae
2. Identify those  for whom the pneum ococcal 
vaccine is recommended
3. Describe the characteristics of the vaccines  
used to prevent pneum ococcal d isease  
(schedule, contraindications, and/or adverse  
reactions)
4. Locate resources relevant to current 
immunization practice
5. Obtain, a s s e s s  and apply patient information to 
determine the need for initial immunization or 
revaccination with a Pneum ococcal vaccine
Pneum ococcal D iseases
• S trep to co ccu s pneum oniae  -- 
Polysaccharide capsule with about 90 
known serotypes
• 5% - 70% of adults have colonization  
of URT
• Infections: pneumonia, bacteremia, 
meningitis (leading cau se  of 
meningitis in pediatrics < 5 yo), 
sinusitis, acute otitis media, 
pharyngitis, and bacteremia
Pneum ococcal D isease  
Epidemiology
• Reservoir 
—Human carriers
• Transmission  
—Respiratory Autoinoculation
• Temporal pattern
—Peaks in Winter, but threat ex ists year- 
round
• Communicability
—Unknown Probably as long as organism  
in respiratory secretions
Pneum ococcal Pneumonia
• 100,000 to 135,000 c a se s  requiring 
hospitalization per year
• R esponsible for up to 1/3 of 
community-acquired pneum onias and 
up to 1/2 of hospital-acquired 
pneum onias
• Common bacterial complication of 
influenza and m easles
• Case-fatality rate 5%-7%, higher in 
elderly
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Clinical Features of 
Pneum ococcal Pneumonia
• Abrupt onset of fever and chills or rigors
• Pleuritic ch est pain
• Cough productive of mucopurulent, rusty 
sputum
• Dyspnea
• Tachypnea
• Hypoxia
• Tachycardia
• Malaise, and w eakness
Pneum ococcal Bacteremia
• More than 50,000 c a se s  per year in the 
United States
• Rates higher am ong elderly and very 
young infants
• Case-fatality rate ~20%; up to 60% 
among the elderly
Pneum ococcal Meningitis
• Estimated 3,000 -6,000 c a se s  per year 
in the United States
• Case-fatality rate ~30%, up to 80% in 
the elderly
• Neurologic seq u elae com m on among 
survivors
• Increased risk in persons with 
cochlear implant
Clinical Features Pneum ococcal 
Meningitis
• Headache
• Lethargy
• Vomiting
• Irritability
• Fever
• Nuchal rigidity
• Cranial nerve sig n s
• Seizures and com a
Conditions that Increase Risk for 
Invasive Pneum ococcal D isease
• Decreased immune function
• Asplenia (functional or anatomic)
• Chronic heart, pulmonary, liver or 
renal d isea se
• Cigarette sm oking
• Cerebrospinal fluid (CSF) leak
Pneum ococcal D isease in 
Children
• Bacteremia without known site  of 
infection m ost com m on clinical 
presentation
• S. pneum oniae  leading cau se  of 
bacterial meningitis among children 
younger than 5 years of age
• Highest rate of meningitis among 
children younger than 1 year of age
• Common cau se  of acute otitis media
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Children at Increased Risk of 
Invasive Pneum ococcal D isease
• Functional or anatomic asplenia, especially  
sickle cell d isease
• HIV infection
• Recipient of cochlear implant
• Out-of-home group child care
• African American children
• Alaska Native and American Indian 
children who live in Alaska, Arizona, or 
New Mexico
• Navajo children who live in Colorado and 
Utah
Pneum ococcal Vaccine
• Two pneum ococcal vaccination  
preparations:
—Pneum ococcal conjugate vaccine  
(PCV13)
—23-Valent pneum ococcal 
polysaccharide vaccine (PPV23)
• Different indications & are NOT 
interchangeable
Pneum ococcal Conjugate Vaccine 
(PCV) (Prevnar®13)
• Pnem ococcal 13-valent conjugate 
vaccine (PCV 13) -- Preservative & 
thimerosal free
• >90% effective against invasive 
d isea se
• Indications for children and adults
PCV13 Recom m endations 
(Children)
• Schedule: All In fa n ts : 4 d ose  series
• D oses at 2, 4, and 6 months; booster d o se  at 
12-15 months
• If a child is unvaccinated, has started but
not com pleted a series of PCV7 or 
PCV13, or com pleted a series of PCV7, 
an age-based schedule to catch-up or 
begin the PCV13 series is available.
PCV13 Recom m endations 
(Children)
• Consider giving children aged 6 -  18 
years who have not received PCV 13 
previously with anatomic or functional 
asplenia, immunocompromising 
conditions, cochlear implant or CSF 
leaks
PCV13 Recom m endations 
(Adults)
• All adults > 65 years
• Adults age 19 through 64 years who  
have not received PCV13, and have 
the following conditions:
— asplenia,
—immunocompromizing conditions 
—cochlear implants 
-C S F  leak
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Pneum ococcal polysaccharide 
vaccine (PPSV) (Pneumovax 23®)
• Mixture of purified capsular 
polysaccharides antigen 23 serotypes
• Not effective in children < 2 years
• 60% - 70 % effective against invasive  
d isea se
• L ess effective in preventing 
pneum ococcal pneumonia
PPSV23 Recom m endations
• Adults 65 years of age or older
• Persons 19 of age and older who  
sm oke or have asthma
• Persons 2 years of age  or older with 
normal immune system  and have a 
chronic illness
—Cardiovascular d isease, pulmonary d isease, 
diabetes, alcoholism , cirrhosis, cerebrospinal 
fluid leak, or cochlear implant
• Persons 2 years of age  and older with 
HIV
PPSV23 Recom m endations, 
continued
• Immunocompromised persons 2 years 
of age or older
—Splenic dysfunction or absence, Hodgkin 
d isease , lymphoma, multiple myeloma, chronic 
renal failure, nephrotic syndrom e or conditions 
such  as organ transplantation with 
im m unosupression, chem otherapy or high- 
d o se  corticosteroid therapy (14 days or longer)
• PPSV should be considered for persons 
living in NH, LTC, certain Native Americans 
(i.e., Alaska Native, Navajo)
PPSV23 and PCV13 
(timing of d o se s  in children)
• Both indicated if > 2 yrs if pt has 
chronic illness
• PPSV 8 w eeks after last d o se  of 
PCV13
• For children with immuno­
com prom ising conditions or asplenia, 
a secon d  d o se  of PPSV23 should be 
given 5 years  after the first d o se  of 
PPSV23.
PPSV23 and PCV13 
(timing of d o se s  in adults) •
• The two vaccines should not be given  
during the sam e visit
• Adults age > 65 years who have not 
received either PCV13 or PPSV23:
—PCV13 is given first, PPSV23 to be given 
6 to 12 months later
• Adults age > 65 years who have received 1 
d ose  of PPSV23 at age > 65 years:
—PCV13 at least 1 year after d ose  of PPSV
PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults > 65 years who have not received 
PCV13, but have received 1 or more d o ses  
of PPSV23 before age 65:
—Administer PCV13 at least 1 year after 
m ost recent PPSV23 dose , then
—Administer a d ose  of PPSV23, 6 to 12 
months after PCV13 (or as soon  as 
possib le after this time window has 
passed), and at least 5 years after the 
m ost recent d ose  of PPSV23
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PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults > 65 years who have received 
PCV13 but not PPSV23 before the age 65:
—Administer PPSV23, 6 to 12 months after 
PCV13
• Adults > 65 years who have received 
PCV13 and 1 or more d o se s  of PPSV23 
before age 65.
—Administer PPSV23, 6 to 12 months after 
PCV13 or as soon  as possib le if this time 
window has passed  and at least 5 years 
after the m ost recent d ose  of PPSV23
PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults age 19 to 64 years with 
immunocompromising conditions or 
asplenia who have not received either 
PCV13or PPSV23
—Administer PCV13 followed by a 1st 
d o se  of PPSV23 at least 8 w eeks 
after PCV13, then a 2nd d o se  of 
PPSV23 at least 5 years  after the 1st 
d o se  of PPSV23
PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults age  19 to 64 years with 
immunocompromising conditions or 
asplenia who have not received 
PCV13, but has received 1 d o se  of 
PPSV23
—Administer PCV13 at least 1 year 
after the PPSV23; administer a 2nd 
d o se  of PPSV23 at least 8 w eeks  
after PCV13 and at least 5 years 
after PPSV23
PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults age 19 to 64 years with 
immunocompromising conditions or 
asplenia who have not received  
PCV13, but has received 2 d o se s  of 
PPSV23:
—Administer PCV13 at least 1 year 
after the m ost recent d o se  of 
PPSV23
PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults age  19 to 64 years with 
immunocompromising conditions or 
asplenia who has received PCV13, but 
not PPSV23:
—Administer PPSV23 at least 8 w eeks  
after PCV13, 2nd d o se  PPSV23 at 
least 5 years after 1st d o se
PPSV23 and PCV13 
(timing of d o se s  in adults)
• Adults age 19 to 64 years with 
immunocompromising conditions or 
asplenia who have received PCV13 
and 1 d o se  PPSV23:
—Administer 2nd d o se  PPSV23 at least 
5 years after 1st d o se  of PPSV23
13
Pneum ococcal V accines Adverse 
Reactions
• Local reactions
—polysaccharide 30%-50% 
—conjugate 5%-49%
• Fever, myalgia 
—polysaccharide <1% 
—conjugate 24%-35%
• Severe adverse rare reactions
Pneum ococcal V accines 
Contraindications and 
Precautions
• Contraindication:
—Severe allergic reaction to vaccine  
com ponent or following prior d o se  
of vaccine
• Precaution:
—Moderate or severe acute illness
Storage and Handling
• Both PPSV and PCV should be stored  
at refrigerator temperature (35°- 46° F) 
[2°- 8° C]).
• Pneum ococcal vaccines must not be 
frozen
Test Your Knowledge
Which patient is a candidate for PPSV?
A. 30 yof who is 32 w eeks pregnant
B. 3 yom with acute otitis media
C. 43 yof who sm okes
D. 64 yom with no chronic illn esses
Test Your Knowledge
D escribe the dosing schedu le of the 
pneum ococcal vaccines for the 
following patients*:
A. 6 5  y o f  - H a s  n o t  r e c e iv e d  a n y  
P n e u m o c o c c a l  v a c c i n e s
B. 8 0  y o m  - R e c e i v e d  1 st d o s e  P P S V  a t  a g e  6 8
C. 6 3  y o f  - R e c e i v e d  1 st d o s e  P P S V  a t  a g e  6 0
D. 6 7  y o m  - R e c e i v e d  1 st d o s e  P P S V  a t  a g e  6 2
*None of the above patients have any immunocompromising conditions.
Selected  R esources for Vaccine 
Information
• CDC Vaccine information
—http://www.cdc.gov/vaccines/acip/
index.html
• Pink Book
—http://www.cdc.gov/vaccines/pubs/
pinkbook/index.html
• Immunization Action Coalition 
—http://www.immunize.org/vis/
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